Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630973 | 0.80 | POLB (0.43) | CYP11B1CYP11B2TNFHTTTDP1 | |
| SCHEMBL9560914 | 0.80 | TDP1 (0.46) | CYP11B1CYP11B2TNFHTTTDP1 | |
| SCHEMBL27561186 | 0.79 | POLB (0.42) | CYP11B1CYP11B2TNFHTTTDP1 | |
| SCHEMBL1618548 | 0.77 | TDP1 (0.48) | CYP11B1CYP11B2TNFHTTTDP1 | |
| SCHEMBL9236926 | 0.76 | TDP1 (0.42) | CYP11B1CYP11B2TNFHTTTDP1 | |
| SCHEMBL22475379 | 0.74 | TDP1 (0.46) | CYP11B1CYP11B2TNFHTTTDP1 | |
| SCHEMBL9092595 | 0.74 | TDP1 (0.46) | CYP11B1CYP11B2TNFHTTTDP1 | |
| SCHEMBL2794591 | 0.74 | TDP1 (0.46) | CYP11B1CYP11B2TNFHTTTDP1 | |
| SCHEMBL2802532 | 0.73 | TDP1 (0.44) | CYP11B1CYP11B2TNFHTTTDP1 | |
| SCHEMBL8435845 | 0.72 | CYP2C9 (0.37) | HTTCYP2C9LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7785630-B2 | Preparation and administration form comprising an acid-labile active compound | NYCOMED GMBH (DE) | 2010-08-31 | — | — | US | claimed |
| EP-2112920-B1 | PROTON PUMP-INHIBITOR-CONTAINING CAPSULES WHICH COMPRISE SUBUNITS DIFFERENTLY STRUCTURED FOR A DELAYED RELEASE OF THE ACTIVE INGREDIENT | INTELLIPHARMACEUTICS CORP (CA) | 2018-07-25 | — | — | EP | disclosed |
| US-9636306-B2 | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient | INTELLIPHARMACEUTICS CORP. (CA) | 2017-05-02 | — | — | US | disclosed |
| US-20160324723-A1 | PHARMACEUTICAL PRODUCT FOR INJECTION | TAKEDA GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20140322312-A1 | PROTON PUMP-INHIBITOR-CONTAINING CAPSULES WHICH COMPRISE SUBUNITS DIFFERENTLY STRUCTURED FOR A DELAYED RELEASE OF THE ACTIVE INGREDIENT | INTELLIPHARMACEUTICS CORP (CA) | 2014-10-30 | — | — | US | disclosed |
| US-8802139-B2 | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient | INTELLIPHARMACEUTICS CORP. (CA) | 2014-08-12 | — | — | US | disclosed |
| US-8603520-B2 | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors | INTELLIPHARMACEUTICS CORP. (CA) | 2013-12-10 | — | — | US | disclosed |
| EP-1341523-B1 | PHARMACEUTICAL PREPARATION IN THE FORM OF A SUSPENSION COMPRISING AN ACID-LABILE ACTIVE INGREDIENT | NYCOMED GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-1525882-B1 | Administration form comprising an acid-labile active compound | NYCOMED GMBH (DE) | 2012-08-08 | — | — | EP | disclosed |
| US-20120083512-A1 | PHARMACEUTICAL PRODUCT FOR INJECTION | NYCOMED GMBH (DE) | 2012-04-05 | — | — | US | disclosed |
| US-20020025342-A1 | Novel administration form comprising an acid-labile active compound | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH | 2002-02-28 | — | — | US | disclosed |
| US-6328993-B1 | Oral administration form for an acid liable active proton pump inhibitor | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-12-11 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0218336-B1 | USE OF BENZYLSULFINYLBENZIMIDAZOLES AS CYTOPROTECTIVE AGENTS FOR THE GASTROINTESTINAL TRACT | NIPPON CHEMIPHAR CO., LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4772619-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1988-09-20 | — | — | US | disclosed |
| US-4721718-A | 2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers | G. D. SEARLE & CO. (US) | 1988-01-26 | — | — | US | disclosed |
| US-4687775-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1987-08-18 | — | — | US | disclosed |
| EP-0218336-A2 | Use of benzylsulfinylbenzimidazoles as cytoprotective agents for the gastrointestinal tract | NIPPON CHEMIPHAR CO., LTD. (JP) | 1987-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | CYP11B1 2831/4885CYP11B2 3447/4885TNF 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.